NCT03905993 (MI) is a clinical trial in Individuality, sponsored by Institut Pasteur.

Who is sponsoring NCT03905993?

NCT03905993 is sponsored by Institut Pasteur.

What condition does NCT03905993 study?

NCT03905993 studies Individuality, Healthy Subjects.

Is NCT03905993 still recruiting?

NCT03905993 is currently completed. Last updated 20 May 2022.

Last reviewed 2022-05-20 · How we verify

NCT03905993: MI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Milieu Intérieur Collection - Genetic & Environmental Determinants Of Immune Phenotype Variance

Completed Last updated 20 May 2022

What this trial tests

trial in Individuality in 956 participants. Completed in 8 August 2013.

Timeline

17 September 2012

Primary endpoint
8 August 2013

8 August 2013

Quick facts

Lead sponsor	Institut Pasteur
Status	Completed
Study type	OBSERVATIONAL
Enrollment	956
Start date	17 September 2012
Primary completion	8 August 2013
Estimated completion	8 August 2013

Conditions studied

Individuality — all drugs for Individuality →
Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Institut Pasteur — full company profile →

Who can join

Adults 20 to 69, any sex, with Individuality or Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the determinants of immunologic variance within the general healthy population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Individuality

Currently open trials in the same condition.

NCT05201534 — Interventions in Mathematics and Cognitive Skills · NA · recruiting

Other Institut Pasteur trials

Trials by the same sponsor.

NCT07205913 — Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND · not yet recruiting
NCT06945822 — Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI · NA · not yet recruiting
NCT05821478 — Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients · Phase 3 · recruiting
NCT06769815 — Host Immunity, Plasmodium and Pathogens Co-Infections · NA · not yet recruiting
NCT06718127 — Description of the Immune Response to Yellow Fever Vaccination · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03905993 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Pasteur
Last refreshed: 20 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03905993.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing